Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating brain atrophy

A brain atrophy and uridine technology, applied in the field of medical nutrition, can solve the problems that the nutritional intake of subjects at risk of neurodegenerative diseases has not been fully studied, and the increase of subjects with brain atrophy

Inactive Publication Date: 2018-12-21
NV NUTRICIA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Studies of improving nutrition in Alzheimer's subjects have shown improved neurocognitive outcomes in the intervention group, but is increasing nutritional intake in subjects with brain atrophy and those at risk for neurodegenerative disease not yet fully studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating brain atrophy
  • Method for treating brain atrophy
  • Method for treating brain atrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1. Clinical Trials

[0073] Carry out randomized, controlled, double-blind, parallel group, multi-national clinical research, wherein 311 prodromal period subjects use composition of the present invention (active composition, every 125ml: 300mg EPA, 1200mg DHA, 106mg phospholipid, 400mg choline, 625mg UMP, 40mg vitamin E, 80mg vitamin C, 60mcg selenium, 3mcg vitamin B12, 1mg vitamin B6, 400mcg folic acid) for 2 years or receive isocaloric control.

[0074] Inclusion criteria for prodromal patients were defined as follows:

[0075] 1) Suffering from episodic memory impairment defined as -1 SD on 2 out of 8 tests (explained further below) with at least a memory test score of -1 SD.

[0076] 2) Evidence of underlying Alzheimer's disease pathology

[0077] - Medial temporal lobe atrophy ≥1 as determined by MRI images

[0078] - Cerebrospinal fluid measurement: beta-amyloid ratio 60 or t-tau >350, or,

[0079] - Abnormal FDG-PET matching changes in Alzheimer's ...

Embodiment 2

[0102] Example 2. Effects of Healthy Rats Exposure to Compositions of the Invention on Synapses

[0103] The added value of vitamin C, vitamin E and selenium according to the invention was evaluated in healthy rats supplemented with uridine (as uridine-5'-monophosphate) and fish oil (FO) containing DHA and EPA.

[0104] Rats were randomized into 4 treatment groups and fed with 1 of 4 intervention diets for 6 weeks (see Table 1). After completing the diet treatment, the rats were sacrificed, and the brain samples were analyzed for phospholipids, synaptic proteins, and 2 enzymes involved in phospholipid synthesis (i.e., choline phosphoryl cytidine transferase (PCYT1A) and choline / ethanolamine phosphotransferase (CEPT1A). ))s level.

[0105] Table 1: Diets containing different amounts of antioxidants, fish oil and UMP.

[0106]

[0107]

[0108] The levels of total and individual phospholipids (except phosphatidylinositol), the levels of the presynaptic protein Synapsin-1...

Embodiment 3

[0113] Example 3: In Vitro Study of the Effects of the Compositions of the Invention on Neuronal Growth

[0114] PC12 pheochromocytoma cells were grown at 37°C in a humidified atmosphere with 95% air and 5% carbon dioxide in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units / ml ) and streptomycin (100 μg / ml) (Gibco). The cells were seeded in a 96-well plate at a density of 2000 cells / well, and the culture medium containing 20 ng / ml nerve growth factor (NGF) was supplemented 24 hours later. Cells were exposed to the composition of the invention or left without supplementation (control). The composition of the cell supplementation is shown in Table 3. Cell replenishment was performed three times. These conditions were compared to unsupplemented cells. After supplementing with these conjugates for 2 days, cells were stained with Calcein-AM stain (2 ng / µl) in 100 µl of medium per well and nuclei were counterstained with Hoechst stain (0.6 µg / m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and / or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and / or slowing down brain atrophy in a human subject in need thereof.

Description

[0001] The present invention is in the field of medical nutrition, more specifically it relates to compositions for the treatment of subjects suffering from brain atrophy or brain shrinkage. Background technique [0002] Brain atrophy is a hallmark of brain aging and is a common feature of many diseases affecting the brain, where the pattern and rate of progression of atrophy depends on the disease involved. Brain shrinkage, or brain atrophy, is described as the loss of neurons and the connections between them, causing a reduction in brain volume. Atrophy can be generalized, meaning that the entire brain has shrunk, or it can be focal, affecting only a limited area of ​​the brain and resulting in reduced function in the areas of the brain that control it. Symptoms of significant brain atrophy include progressive cognitive impairment involving multiple cognitive functions, also known as dementia, seizures, and aphasia, which is the disruption of language understanding or produc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/04A61K31/202A61K31/375A61K31/7068A61K31/7072A61P25/28
CPCA61K31/202A61K31/375A61K31/7068A61K31/7072A61K31/04A61K31/22A61P25/28A61P43/00A61K2300/00
Inventor M·C·德维尔德
Owner NV NUTRICIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com